Eltrombopag — Discount Pricing

Other medications in Blood Disorders

• Emicizumab
• Epoetin Alfa
• Factor IX
• Factor VIII
• Filgrastim
• Hydroxyurea
• L-Glutamine
• Luspatercept

About Eltrombopag

Eltrombopag, known by brand names like Promacta and Revolade, is a vital medication for individuals managing specific blood disorders that affect platelet counts. This powerful treatment helps your body produce more platelets, crucial for blood clotting. At TheDrugClub, we understand the importance of accessing essential medications like eltrombopag, and we're dedicated to helping our members find significant savings.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Eltrombopag is approved for (FDA label)

Eltrombopag tablet is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag tablets should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. (1.1) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.

Source: Read the full FDA label on DailyMed. Label effective date: July 2, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Eltrombopag (FDA label)

WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation [see Warnings and Precautions (5.1) ]. Eltrombopag tablets may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended [see Warnings and Precautions (5.2) ]. WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY See full prescribing information for complete boxed warning. In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation. (5.1) Eltrombopag may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended. (5.2)

Source: FDA prescribing information (DailyMed). Set ID: 9af1e314-91ca-4ebc-ac12-f9fddc6d7902. SPL document ID: 559faef5-e02d-a82b-e063-6294a90ae8da. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Eltrombopag (FDA label)

Tablets • 12.5 mg tablets — Off-white, round, bevel edged, biconvex film-coated tablets debossed with 'H' on one side and 'E10' on the other side. Each tablet, for oral administration, contains eltrombopag olamine, equivalent to 12.5 mg of eltrombopag free acid. • 25 mg tablets — Beige colored, round, bevel edged, biconvex film-coated tablets debossed with 'H' on one side and 'E11' on the other side. Each tablet, for oral administration, contains eltrombopag olamine, equivalent to 25 mg of eltrombopag free acid. • 50 mg tablets — Off-white, round, bevel edged, biconvex film-coated tablets debossed with 'H' on one side and 'E12' on the other side.

Source: FDA prescribing information (DailyMed). Set ID: 9af1e314-91ca-4ebc-ac12-f9fddc6d7902. SPL document ID: 559faef5-e02d-a82b-e063-6294a90ae8da. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Eltrombopag (FDA label)

The following clinically significant adverse reactions associated with eltrombopag are described in other sections. • Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1) ] • Hepatotoxicity [see Warnings and Precautions (5.2) ] • Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia [see Warnings and Precautions (5.3) ] • Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.4) ] • Cataracts [see Warnings and Precautions (5.5) ] Across all indications, the most common adverse reactions (≥ 20% in any indication) were: anemia, nausea, pyrexia, alanine aminotransferase increased, cough, fatigue, headache, and diarrhea. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact XLCare Pharmaceuticals, Inc. at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 9af1e314-91ca-4ebc-ac12-f9fddc6d7902. SPL document ID: 559faef5-e02d-a82b-e063-6294a90ae8da. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Eltrombopag (FDA label)

• Hepatotoxicity: Monitor liver function before and during therapy. (5.2) • Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia. (5.3) • Thrombotic/Thromboembolic Complications: Portal vein thrombosis has been reported in patients with chronic liver disease receiving eltrombopag. Monitor platelet counts regularly. (5.4) 5.1 Hepatic Decompensation in Patients With Chronic Hepatitis C In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation. In two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, ascites and encephalopathy occurred more frequently on the arm receiving treatment with eltrombopag plus antivirals (7%) than the placebo plus antivirals arm (4%).

Source: FDA prescribing information (DailyMed). Set ID: 9af1e314-91ca-4ebc-ac12-f9fddc6d7902. SPL document ID: 559faef5-e02d-a82b-e063-6294a90ae8da. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Eltrombopag (FDA label)

7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids. Take eltrombopag at least 2 hours before or 4 hours after any medications or products containing polyvalent cations, such as antacids, dairy products, and mineral supplements to avoid significant reduction in absorption of eltrombopag due to chelation [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ]. 7.2 Transporters Use caution when concomitantly administering eltrombopag and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan).

Source: FDA prescribing information (DailyMed). Set ID: 9af1e314-91ca-4ebc-ac12-f9fddc6d7902. SPL document ID: 559faef5-e02d-a82b-e063-6294a90ae8da. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.